Lucid Diagnostics raises $15.3M in registered direct offering of 13.9M shares at $1.10/share

Lucid Diagnostics Inc.

Gross proceeds of ~$15.3M from sale of 13,939,331 shares at $1.10/share; net proceeds ~$14.5M after fees/expenses.
Offering expected to close on March 5, 2025; Canaccord Genuity acting as sole placement agent.
Proceeds to be used for working capital and general corporate purposes; offering made under effective Form S-3 shelf.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.